Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jerome D. Winegarden"'
Publikováno v:
International Journal of Cancer Care and Delivery.
Autor:
Paul M. Barr, Hongli Li, Brad S. Kahl, Jerome D. Winegarden, Louis S. Constine, Lode J. Swinnen, Michael LeBlanc, Jonathan W. Friedberg, Joo Y. Song, Thomas P. Miller, Thomas J. Fitzgerald, John P. Leonard, Richard I. Fisher, Steven I. Park, Daniel O. Persky, Sonali M. Smith, Deborah M. Stephens, Lisa M. Rimsza, Nancy L. Bartlett
Publikováno v:
J Clin Oncol
PURPOSE Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The pref
Autor:
Joel N. Saltzman, Alan P. Lyss, Chandra P. Belani, Mohammed A. Kassem, Jerome D. Winegarden, Joan H. Schiller, Thomas E. Stinchcombe, Suzanne E. Dahlberg, Gopakumar S. Nambudiri, Nathan A. Pennell, John McCann, Leora Horn, Mohamed K. Mohamed, Jan M. Rothman, Suresh S. Ramalingam
PURPOSE Pemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non–small-cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated efficacy. We conducted a randomized study to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::400ca8732da050ca587406a048512f38
https://europepmc.org/articles/PMC7001786/
https://europepmc.org/articles/PMC7001786/
Autor:
Richard I. Fisher, Hongli Li, Lode J. Swinnen, Paul M. Barr, Brad S. Kahl, Lisa M. Rimsza, Jerome D. Winegarden, Michael LeBlanc, Nancy L. Bartlett, Thomas J. Fitzgerald, Steven I. Park, Deborah M. Stephens, Jonathan W. Friedberg, Sonali M. Smith, Joo Y. Song, Louis S. Constine, John P. Leonard, Daniel O. Persky
Publikováno v:
Blood. 134:349-349
Introduction Limited stage disease accounts for 30-40% of Diffuse Large B-cell Lymphoma (DLBCL), with better overall survival than advanced stage disease, but with increased late relapses regardless of treatment strategy (Stephens 2016). Preferred tr
Autor:
Bertram Schnitzer, Jaspreet S. Grewal, Lauren B. Smith, Joseph A. Tworek, Jerome D. Winegarden, John C. Krauss
Publikováno v:
Annals of Hematology. 86:499-508
Anaplastic large cell lymphoma (ALCL) is an aggressive neoplasm of T- or null cell phenotype and is recognized as a distinct clinicopathologic subtype of non-Hodgkin lymphoma (NHL) in the revised World Health Organization (WHO) classification of hema
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
Autor:
Stuart A. Krauss, Philip C. Hoffman, Jerome D. Winegarden, Ann M. Mauer, Charles M. Rudin, Thomas F. Gajewski, Everett E. Vokes
Publikováno v:
Lung Cancer. 39:191-196
Background: Bryostatin-1 is a macrocyclic lactone, which exhibits pleiotropic biological effects via protein kinase C and has shown preclinical synergy with paclitaxel for enhanced tumor cell apoptosis. Patients and Methods: Patients had stage IIIB (
Autor:
Jeanne Winn, Bonita Singal, Raju Kumar Vaddepally, Jan A. Akervall, Jerome D. Winegarden, Vijay Damarla, Samir Narayan
Publikováno v:
Journal of Clinical Oncology. 33:e17523-e17523
e17523 Background: We evaluated the impact of single day multidisciplinary clinics (MDC) on the lead time from diagnosis to treatment in head and neck cancers compared with patients prior to the im...
Autor:
Charles M. Rudin, Everett E. Vokes, Miguel A. Villalona-Calero, Philip C. Hoffman, Kristen Kasza, Jerome D. Winegarden, Livia Szeto, Gregory A. Otterson, Ann M. Mauer, V. J. Lanzotti
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(6)
Purpose To evaluate the efficacy and toxicity of oxaliplatin and paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods The treatment regimen was given as defined in a phase I investigatio
Autor:
M. Eileen Dolan, Philip C. Hoffman, Jerome D. Winegarden, Livia Szeto, Ann M. Mauer, Everett E. Vokes, Charles M. Rudin
Publikováno v:
Lung Cancer. 41:S91-S92
Autor:
Jerome D. Winegarden, Ann M. Mauer, Mark Kozloff, D. Gustin, Stuart J. Wong, Everett E. Vokes, Ezra E.W. Cohen
Publikováno v:
Journal of Clinical Oncology. 22:5539-5539
5539 Background: Studies of EGFR inhibitors in SCCHN have demonstrated reproducible activity. Preclinical studies have implicated angiogenesis as a mechanism of resistance to these agents. Furthermore, angiogenesis has been linked with tumor progress